DDrare: Database of Drug Development for Rare Diseases

Armodafinil (DrugBank: Armodafinil)

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
13	Multiple sclerosis/Neuromyelitis optica	1
84	Sarcoidosis	1

6. Parkinson disease [ 2,123 clinical trials, 2,046 drugs, (DrugBank: 324 drugs), 183 drug target genes, 198 drug target pathways]

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,123 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01256905 (ClinicalTrials.gov)	December 2010	8/12/2010	Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies	Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies	Parkinsons Disease;Lewy Bodies Disease	Drug: Armodafinil	New York University	Cephalon	Recruiting	50 Years	80 Years	Both	20	N/A	United States

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00981084 (ClinicalTrials.gov)	September 2009	18/9/2009	Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)	The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study	Multiple Sclerosis	Drug: armodafinil	University of Missouri, Kansas City	University of Kansas	Completed	18 Years	60 Years	All	33	Phase 2;Phase 3	United States

84. Sarcoidosis [ 143 clinical trials, 221 drugs, (DrugBank: 79 drugs), 82 drug target genes, 165 drug target pathways]

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 143 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00555347 (ClinicalTrials.gov)	October 2007	7/11/2007	Use of Armodafinil for Fatigue in Sarcoidosis	Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis	Sarcoidosis;Fatigue;Sleepiness	Drug: Armodafinil;Drug: Placebo	University of Cincinnati	Cephalon	Completed	18 Years	N/A	Both	20	Phase 2;Phase 3	United States